Opendata, web and dolomites

EVOLVE SIGNED

Extracellular Vesicle-Internalizing Receptors (EVIRs) for Cancer ImmunoGeneTherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EVOLVE project word cloud

Explore the words cloud of the EVOLVE project. It provides you a very rough idea of what is the project "EVOLVE" about.

ancillary    ev    transformative    clones    mouse    evolve    vaccines    barriers    anti    gene    broadening    whereby    platform    tumor    exposed    optimize    hence    conditioning    modality    elicit    witnessing    durable    dramatic    outside    largely    immunotherapies    immunity    therapeutic    vaccination    strategies    inactivated    administration    envisions    efficient    deployment    microenvironment    shortcomings    immunotherapy    preclinical    presentation    clinical    breast    reactive    models    previously    presenting    propel    cross    cancer    immune    engineering    extracellular    evs    stimulating    designed    prospectively    leverage    puts    human    patients    overcomes    inoculation    delivered    cells    melanoma    trials    unsatisfactory    eradication    cell    strategy    vesicles    innovative    highlighting    combined    combination    regressions    evirs    apc    treatments    abating    antigens    cellmediated    transfer    chimeric    hurdles    technologies    primarily    box    pathogens    interventions    receptors    apcs    antigen   

Project "EVOLVE" data sheet

The following table provides information about the project.

Coordinator
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE 

Organization address
address: BATIMENT CE 3316 STATION 1
city: LAUSANNE
postcode: 1015
website: www.epfl.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 1˙958˙919 €
 EC max contribution 1˙958˙919 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-COG
 Funding Scheme ERC-COG
 Starting year 2017
 Duration (year-month-day) from 2017-07-01   to  2022-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) coordinator 1˙958˙919.00

Map

 Project objective

We are witnessing transformative results in the clinical application of both cancer immunotherapies and gene transfer technologies. Tumor vaccines are a specific modality of cancer immunotherapy. Similar to vaccination against pathogens, tumor vaccines are designed to elicit a specific immune response against cancer. They are based on the administration of inactivated cancer cells or tumor antigens, or the inoculation of antigen-presenting cells (APCs) previously exposed to tumor antigens. In spite of significant development and testing, tumor vaccines have largely delivered unsatisfactory clinical results. Indeed, while some patients show dramatic and durable cancer regressions, many do not respond, highlighting both the potential and the shortcomings of current vaccination strategies. Hence, identifying and abating the barriers to effective cancer vaccines is key to broadening their therapeutic reach. The goal of EVOLVE (EVirs to Optimize and Leverage Vaccines for cancer Eradication) is to propel the development of effective APC-based tumor vaccines using an innovative strategy that overcomes several key hurdles associated with available treatments. EVOLVE puts forward a novel APC engineering platform whereby chimeric receptors are used to both enable the specific and efficient uptake of cancer-derived extracellular vesicles (EVs) into APCs, and to promote the cross-presentation of EV-associated tumor antigens for stimulating anti-tumor immunity. EVOLVE also envisions a combination of ancillary ‘outside of the box’ interventions, primarily based on further APC engineering combined with innovative pre-conditioning of the tumor microenvironment, to facilitate the deployment of effective APC-driven, T-cellmediated anti-tumor immunity. Further to preclinical trials in mouse models of breast cancer and melanoma, our APC platform will be used to prospectively identify novel human melanoma antigens and reactive T cell clones for broader immunotherapy applications.

 Publications

year authors and title journal last update
List of publications.
2019 Chiara Cianciaruso, Tim Beltraminelli, Florent Duval, Sina Nassiri, Romain Hamelin, André Mozes, Hector Gallart-Ayala, Gerardo Ceada Torres, Bruno Torchia, Carola H. Ries, Julijana Ivanisevic, Michele De Palma
Molecular Profiling and Functional Analysis of Macrophage-Derived Tumor Extracellular Vesicles
published pages: 3062-3080.e11, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2019.05.008
Cell Reports 27/10 2020-01-29
2019 Caleb R. Perez, Michele De Palma
Engineering dendritic cell vaccines to improve cancer immunotherapy
published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-019-13368-y
Nature Communications 10/1 2020-01-29
2018 Mario Leonardo Squadrito, Chiara Cianciaruso, Sarah K Hansen, Michele De Palma
EVIR: chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens
published pages: 183-186, ISSN: 1548-7091, DOI: 10.1038/nmeth.4579
Nature Methods 15/3 2019-03-11
2019 Ioanna Keklikoglou, Chiara Cianciaruso, Esra Güç, Mario Leonardo Squadrito, Laura M. Spring, Simon Tazzyman, Lore Lambein, Amanda Poissonnier, Gino B. Ferraro, Caroline Baer, Antonino Cassará, Alan Guichard, M. Luisa Iruela-Arispe, Claire E. Lewis, Lisa M. Coussens, Aditya Bardia, Rakesh K. Jain, Jeffrey W. Pollard, Michele De Palma
Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models
published pages: 190-202, ISSN: 1465-7392, DOI: 10.1038/s41556-018-0256-3
Nature Cell Biology 21/2 2019-03-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EVOLVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EVOLVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More  

FICOMOL (2019)

Field Control of Cold Molecular Collisions

Read More  

iNANOVAC4CANCER (2019)

BIOHYBRID AND BIODEGRADABLE NANOVACCINES FOR CANCER IMMUNOTHERAPY

Read More